SANTA MONICA, Calif., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced upcoming oral presentations related to KTE-C19, the Company's most advanced product candidate, that will take place at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014. KTE-C19 is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy that involves genetically modifying a patient's T cells to express a CAR designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. The scheduled presentations are:
2014 ASH Annual Meeting Presentations
- "Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma"
Date: Monday, December 8, 2014: 3:30 PM Pacific
Session: 801. Gene Therapy and Transfer I
Abstract number: 550
Location: Moscone Center, South Building, Gateway Ballroom 104
Presenter: James N Kochenderfer, M.D., Investigator, Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute
- "Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia"
Date: Monday, December 8, 2014: 11:00 AM Pacific
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Immunotherapeutic Trials in ALL
Abstract number: 381
Location: Moscone Center, West Building, 3009-3011-3022-3024
Presenter: Daniel W. Lee III, M.D., Assistant Clinical Investigator, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute
- "Curative Potential of Cell Transfer Therapy for Cancer"
Date: Sunday, December 7, 2014: 9:30 AM-11:00 AM Pacific
Session: Special Scientific Symposium on Chimeric Antigen Receptor T-Cell Therapy
Location: Moscone Center, West Building, 3007-3009-3011-3020-3022-3024
Presenter: Steven A. Rosenberg, M.D., Ph.D., Chief, Surgery Branch, Head, Tumor Immunology Section, Center for Cancer Research, National Cancer Institute
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
CONTACT: Kite Contact: Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Kimberly Minarovich Burns McClellan (212) 213-0006 firstname.lastname@example.org
Source:Kite Pharma, Inc.